Substituted 1,2,3,4-tetrahydroisoquinoline derivatives

Abstract

The invention relates to novel 1,2,3,4-tetrahydroisoquinoline derivatives of formula (I) wherein R 1 , R 2 , R 3 and X are as defined in the claims, and their use as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects including processes for the preparation of the compounds, pharmaceutical compositions containing one or more of those compounds and methods of treatment comprising administration of said compounds to a mammal.

1 . (canceled) 
     
     
         2 . A 1,2,3,4-tetrahydroisoquinoline derivative according to  claim 15  wherein R 1  and R 2  both represent a C 1 -C 4  alkoxy group. 
     
     
         3 . A 1,2,3,4-tetrahydroisoquinoline derivative according to  claim 2  wherein R 1  and R 2  both represent a methoxy group. 
     
     
         4 . A 1,2,3,4-tetrahydroisoquinoline derivative according to  claim 15  wherein X represents a nitrogen atom. 
     
     
         5 . A 1,2,3,4-tetrahydroisoquinoline derivative according to  claim 15  wherein X represents —CH—. 
     
     
         6 . A 1,2,3,4-tetrahydroisoquinoline derivative according to  claim 15  wherein R 3  represents a methyl group. 
     
     
         7 . A 1,2,3,4-tetrahydroisoquinoline derivative according to  claim 15  wherein R 1  and R 2  represent a methoxy group, X represents —CH— and R 3  represents C 1 -C 6 -alkyl. 
     
     
         8 . (canceled) 
     
     
         9 . (canceled) 
     
     
         10 . A pharmaceutical composition comprising at least one compound according to  claim 15  and a pharmaceutically acceptable carrier material. 
     
     
         11 . (canceled) 
     
     
         12 . (canceled) 
     
     
         13 . (canceled) 
     
     
         14 . (canceled) 
     
     
         15 . A 1,2,3,4-tetrahydroisoquinoline derivative of the general formula (I) 
       
         
           
           
               
               
           
         
         wherein: 
         R 1  and R 2  independently represent hydrogen or C 1 -C 4  alkoxy; 
         R 3  represents C 1 -C 6 -alkyl; 
         X represents —CH— or a nitrogen atom; 
         or a pharmaceutically acceptable salt, solvent complex or morphological form, thereof. 
       
     
     
         16 . A 1,2,3,4-tetrahydroisoquinoline derivative according to  claim 2  wherein X represents a nitrogen atom. 
     
     
         17 . A 1,2,3,4-tetrahydroisoquinoline derivative according to  claim 2  wherein X represents —CH—. 
     
     
         18 . A 1,2,3,4-tetrahydroisoquinoline derivative according to  claim 2  wherein R 3  represents a methyl group. 
     
     
         19 . A 1,2,3,4-tetrahydroisoquinoline derivative according to  claim 3  wherein X represents a nitrogen atom. 
     
     
         20 . A 1,2,3,4-tetrahydroisoquinoline derivative according to  claim 3  wherein X represents —CH—. 
     
     
         21 . A 1,2,3,4-tetrahydroisoquinoline derivative according to  claim 3  wherein R 3  represents a methyl group. 
     
     
         22 . A method of preventing or treating a disorder or disease selected from the group consisting of eating disorders or sleep disorders, comprising administering to a subject in need thereof an effective amount of the 1,2,3,4-tetrahydroisoquinoline derivative according to  claim 15 . 
     
     
         23 . A method according to  claim 22  wherein said disorder or disease is a sleep disorder. 
     
     
         24 . A method according to  claim 23  wherein said sleep disorder is selected from the group consisting of insomnias, sleep-related dystonias, restless leg syndrome, sleep apneas, jet-lag syndrome, shift-work syndrome, delayed or advanced sleep phase syndrome.